Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

•Few treatments for metastatic melanoma provide long term tumor regressions.•Response rate of 15.6% observed in 143 patients treated with tremelimumab.•Patients with tumor response to tremelimumab very likely to have durable responses.•Ten and 12.5year estimated survival rates of 16% observed in these patients.•Anti-CTLA-4 memory immune responses against tumors can last beyond a decade.